Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Iron deficiency is a condition resulting from inadequate iron levels in the body, leading to impaired hemoglobin synthesis and reduced oxygen transport. It is a common cause of anemia, characterized by fatigue, weakness, and other symptoms. The condition arises from insufficient dietary intake, increased iron requirements, malabsorption, or chronic blood loss. Diagnosis involves assessing iron stores and blood parameters. Treatment includes oral or intravenous iron supplementation, addressing underlying causes of blood loss, and dietary modifications. Hepcidin regulation plays a crucial role in iron homeostasis and is a target for investigational therapies.
Iron supplements replenish iron stores, enabling increased hemoglobin production and improved oxygen carrying capacity. Hepcidin modulators (investigational) aim to restore iron availability by reducing hepcidin levels and promoting iron release from stores and increasing intestinal absorption.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Iron Deficiency (IDA).